Compare AENT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | DCTH |
|---|---|---|
| Founded | 1990 | 1988 |
| Country | United States | United States |
| Employees | 697 | N/A |
| Industry | Durable Goods | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.0M | 363.5M |
| IPO Year | N/A | 2015 |
| Metric | AENT | DCTH |
|---|---|---|
| Price | $5.90 | $10.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $10.00 | ★ $22.00 |
| AVG Volume (30 Days) | 23.1K | ★ 478.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.44 | $24.54 |
| Revenue Next Year | $1.64 | $33.15 |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $8.12 |
| 52 Week High | $8.80 | $17.34 |
| Indicator | AENT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 44.10 |
| Support Level | $5.19 | $9.87 |
| Resistance Level | $7.53 | $11.14 |
| Average True Range (ATR) | 0.66 | 0.52 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 25.83 | 2.42 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.